Aerovate Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AVTE and other ETFs, options, and stocks.

About AVTE

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.

CEO

Timothy P. Noyes

CEOTimothy P. Noyes

Employees

Employees30

Headquarters

Waltham, Massachusetts

HeadquartersWaltham, Massachusetts

Founded

2018

Founded2018

Employees

Employees30

AVTE Key Statistics

Market cap

77.68M

Market cap77.68M

Price-Earnings ratio

-1.10

Price-Earnings ratio-1.10

Dividend yield

—

Dividend yield—

Average volume

1.02M

Average volume1.02M

High today

$2.70

High today$2.70

Low today

$2.42

Low today$2.42

Open price

$2.67

Open price$2.67

Volume

1.12M

Volume1.12M

52 Week high

$25.29

52 Week high$25.29

52 Week low

$1.25

52 Week low$1.25

Aerovate Therapeutics

Why Robinhood?

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. Show more

AVTE Key Statistics

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.